FCGR2A and neoplasm: Dual targeting of the adaptive and innate compartments is further supported by pembrolizumab plus cetuximab: cetuximab engages FcγRIIIa on NK cells (ADCC) and FcγR on macrophages (ADCP), while PD-1 blockade reinvigorates effectors; however, macrophage ‘walls’ at tumor margins and FcγR polymorphisms may modulate benefit, motivating assays of myeloid exclusion and Fc competence (90, 91).